A Study of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer Naive to Chemotherapy
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of Tarceva in two groups of patients with
non-small cell lung cancer who have not been pre-treated with chemotherapy. One group,
consisting of patients who have never smoked, will receive Tarceva 150 mg/day, and the other
group, consisting of current/former smokers, will receive Tarceva 150 mg/day increasing to a
maximum of 300 mg/day. The anticipated time on study treatment is 1-2 years.